PMID- 22025960
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111110
LR  - 20220310
IS  - 2005-6745 (Electronic)
IS  - 2005-6737 (Print)
IS  - 2005-6737 (Linking)
VI  - 52
IP  - 9
DP  - 2011 Sep
TI  - Changes in sexual function in benign prostatic hyperplasia patients taking 
      dutasteride: 1-year follow-up results.
PG  - 632-6
LID - 10.4111/kju.2011.52.9.632 [doi]
AB  - PURPOSE: Sexual adverse events (AEs), a major cause for discontinuing 
      5alpha-reductase inhibitor (5ARI) therapy for benign prostatic hyperplasia (BPH), are 
      known to occur most frequently early in therapy and appear to decline over time. 
      The aim of this study was to investigate the changes in sexual function occurring 
      with dutasteride treatment during a 1-year follow-up period in Korean men. 
      MATERIALS AND METHODS: Using the International Index of Erectile Function, we 
      prospectively evaluated, after 1, 3, 6, 9, and 12 months of treatment, the 
      changes in sexual function of 55 outpatients (mean age 62.3+/-7.2 years) with BPH 
      (mean volume 48.9+/-16.0 g) who had relatively good erectile function (EF) and were 
      treated with dutasteride for at least 1 year. RESULTS: EF scores showed the most 
      significant decrease at 1 month (p<0.01). Function gradually recovered thereafter 
      but was still significantly decreased after 12 months of treatment (p<0.05). The 
      scores for orgasmic function and sexual desire also showed the most significant 
      reduction at 1 month but were restored to the baseline level at 6 months. No 
      significant correlation was observed between changes in sexual function and 
      prostate-specific antigen level, prostate volume, or International Prostate 
      Symptom Scores. CONCLUSIONS: After 1 month of treatment, dutasteride therapy 
      resulted in a significant reduction in all investigated sexual functions. 
      Overall, recovery in sexual function was noted at 3 months, and orgasmic function 
      and sexual desire were restored to baseline levels at 6 months. However, EF was 
      still significantly reduced at 12 months.
FAU - Chi, Byung Hoon
AU  - Chi BH
AD  - Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea.
FAU - Kim, Sae Chul
AU  - Kim SC
LA  - eng
PT  - Journal Article
DEP - 20110928
PL  - Korea (South)
TA  - Korean J Urol
JT  - Korean journal of urology
JID - 101499376
PMC - PMC3198238
OTO - NOTNLM
OT  - Dutasteride
OT  - Erectile dysfunction
OT  - Prostatic hyperplasia
COIS- The authors have nothing to disclose.
EDAT- 2011/10/26 06:00
MHDA- 2011/10/26 06:01
PMCR- 2011/09/01
CRDT- 2011/10/26 06:00
PHST- 2011/02/23 00:00 [received]
PHST- 2011/08/02 00:00 [accepted]
PHST- 2011/10/26 06:00 [entrez]
PHST- 2011/10/26 06:00 [pubmed]
PHST- 2011/10/26 06:01 [medline]
PHST- 2011/09/01 00:00 [pmc-release]
AID - 10.4111/kju.2011.52.9.632 [doi]
PST - ppublish
SO  - Korean J Urol. 2011 Sep;52(9):632-6. doi: 10.4111/kju.2011.52.9.632. Epub 2011 
      Sep 28.